Please ensure Javascript is enabled for purposes of website accessibility

Why Endo International Shares Are Jumping Today

By Keith Speights – Jul 7, 2020 at 10:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An FDA approval boosted the pharma stock.

What happened

Shares of Endo International (ENDP -5.47%) were jumping 5.7% higher as of 11:26 a.m. EDT on Tuesday after rising as much as 15.6% earlier in the day. The gain came following the drugmaker's announcement on Monday evening that the FDA approved Qwo for treating moderate to severe cellulite in the buttocks of adult women.

So what

Investors cheered the FDA approval of Qwo for good reason. The agency's thumbs-up for the cellulite treatment marked Endo's move into medical aesthetics, a potentially lucrative arena for the company.

Qwo bottles and packaging

Image source: Endo International. 

Qwo is the first injectable treatment for cellulite approved by the FDA. Cellulite is caused by multiple factors. One key contributing factor is fibrous septae -- connective tissues that connect skin to the fascia and cause dimpling. Qwo seems to work by releasing the fibrous septae and thereby smoothing the skin.

Endo included a statement from board-certified dermatologist Anne Chapas in its press release announcing the FDA approval of Qwo. Chapas said that the product "could be a game-changer for many women with cellulite." 

Now what

Don't expect Qwo to make a financial impact on the pharma stock anytime soon. Endo decided to delay its launch of the product until 2021 due to the COVID-19 pandemic. The company said that Qwo should be available in aesthetic healthcare practitioners' offices beginning next spring.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Endo International plc Stock Quote
Endo International plc
$0.10 (-5.47%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.